@article{VoglLutzSchoenfelderetal.2015, author = {Vogl, Silvia and Lutz, Roman W. and Sch{\"o}nfelder, Gilbert and Lutz, Werner K.}, title = {CYP2C9 genotype vs. metabolic phenotype for individual drug dosing - a correlation analysis using flurbiprofen as probe drug}, series = {PLoS ONE}, volume = {10}, journal = {PLoS ONE}, number = {3}, doi = {10.1371/journal.pone.0120403}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148783}, pages = {e0120403}, year = {2015}, abstract = {Currently, genotyping of patients for polymorphic enzymes responsible for metabolic elimination is considered a possibility to adjust drug dose levels. For a patient to profit from this procedure, the interindividual differences in drug metabolism within one genotype should be smaller than those between different genotypes. We studied a large cohort of healthy young adults (283 subjects), correlating their CYP2C9 genotype to a simple phenotyping metric, using flurbiprofen as probe drug. Genotyping was conducted for CYP2C9*1, *2, *3. The urinary metabolic ratio MR (concentration of CYP2C9-dependent metabolite divided by concentration of flurbiprofen) determined two hours after flurbiprofen (8.75 mg) administration served as phenotyping metric. Linear statistical models correlating genotype and phenotype provided highly significant allele-specific MR estimates of 0.596 for the wild type allele CYP2C9*1, 0.405 for CYP2C9*2 (68 \% of wild type), and 0.113 for CYP2C9*3 (19 \% of wild type). If these estimates were used for flurbiprofen dose adjustment, taking 100 \% for genotype *1/*1, an average reduction to 84 \%, 60 \%, 68 \%, 43 \%, and 19\% would result for genotype *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively. Due to the large individual variation within genotypes with coefficients of variation >= 20\% and supposing the normal distribution, one in three individuals would be out of the average optimum dose by more than 20 \%, one in 20 would be 40\% off. Whether this problem also applies to other CYPs and other drugs has to be investigated case by case. Our data for the given example, however, puts the benefit of individual drug dosing to question, if it is exclusively based on genotype.}, language = {en} } @article{VandenbergChahoudHeindeletal.2012, author = {Vandenberg, Laura N. and Chahoud, Ibrahim and Heindel, Jerrold J. and Padmanabhan, Vasantha and Paumgartten, Francisco J. R. and Sch{\"o}nfelder, Gilbert}, title = {Urinary, Circulating, and Tissue Biomonitoring Studies Indicate Widespread Exposure to Bisphenol A}, series = {Ci{\^e}ncia \& Sa{\´u}de Coletiva}, volume = {17}, journal = {Ci{\^e}ncia \& Sa{\´u}de Coletiva}, number = {2}, doi = {10.1289/ehp.0901716}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134332}, pages = {407-434}, year = {2012}, abstract = {Bisphenol A (BPA) is one of the highest-volume chemicals produced worldwide, and human exposure to BPA is thought to be ubiquitous. Thus, there are concerns that the amount of BPA to which humans are exposed may cause adverse health effects. We examined many possibilities for why biomonitoring and toxicokinetic studies could come to seemingly conflicting conclusions. More than 80 published human biomonitoring studies that measured BPA concentrations in human tissues, urine, blood, and other fluids, along with two toxicokinetic studies of human BPA metabolism were examined. Unconjugated BPA was routinely detected in blood (in the nanograms per milliliter range), and conjugated BPA was routinely detected in the vast majority of urine samples (also in the nanograms per milliliter range). In stark contrast, toxicokinetic studies proposed that humans are not internally exposed to BPA. Available data from biomonitoring studies clearly indicate that the general population is exposed to BPA and is at risk from internal exposure to unconjugated BPA. The two toxicokinetic studies that suggested human BPA exposure is negligible have significant deficiencies, are directly contradicted by hypothesis-driven studies, and are therefore not reliable for risk assessment purposes.}, language = {en} } @article{BertChmielewskaBergmannetal.2016, author = {Bert, Bettina and Chmielewska, Justyna and Bergmann, Sven and Busch, Maximilian and Driever, Wolfgang and Finger-Baier, Karin and H{\"o}ßler, Johanna and K{\"o}hler, Almut and Leich, Nora and Misgeld, Thomas and N{\"o}ldner, Torsten and Reiher, Annegret and Schartl, Manfred and Seebach-Sproedt, Anja and Thumberger, Thomas and Sch{\"o}nfelder, Gilbert and Grune, Barbara}, title = {Considerations for a European animal welfare standard to evaluate adverse phenotypes in teleost fish}, series = {The EMBO Journal}, volume = {35}, journal = {The EMBO Journal}, number = {11}, doi = {10.15252/embj.201694448}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-188783}, pages = {1151-1154}, year = {2016}, abstract = {No abstract available.}, language = {en} }